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ABSTRAcT
Objectives: Obesity is a significant contributor to metabolic complications. However, such compli-
cations are not uniform in people with similar body-size. The existence of normal-weight individuals 
with and obese individuals without metabolic complications has been described in the general 
population and is important in the context of cardiovascular disease (CVD). This has not been inves-
tigated in rheumatoid arthritis (RA), a condition associated with increased cardiometabolic risk. This 
study aims to identify the prevalence and predictors of body-size phenotypes in RA and investigate 
their associations with CVD risk. Methods: Body mass index (BMI: kg/m2), body fat (BF) and fat 
free mass (FFM), RA characteristics and CVD risk factors were assessed in 363 (262 female) volun-
teers with RA. Abnormal cardiometabolic status was defined as the presence of >1 of the following: 
hypertension, increased triglycerides or increased Low or reduced High Density Lipoprotein, high 
glucose, insulin resistance. Results: Among normal-weight, overweight, and obese participants, 
25%, 45.8%, 57.1% respectively were metabolically abnormal. Old age (B= 1.032, err=0.011; p= 
0.005), waist circumference (B= 1.057, err= 0.011; p= 0.000), and smoking cessation (B= 1.425, 
err= 0.169; p=0.036) were significant predictors for metabolic abnormality. Conclusions: A sig-
nificant number of RA patients present with different body-size and metabolic phenotypes. Body 
Mass Index alone is not a sufficient indicator of cardiometabolic risk in RA; this may have significant 
implications in their CVD risk evaluation. Body fat distribution seems to 
be a significant contributor to such abnormalities. Further research is 
needed, focusing on the metabolic properties of specific adipose de-
pots of RA patients.
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IntROduCtIOn
Obesity associates with cardiometabolic abnormalities, 
such as reduced insulin sensitivity, hyperlipidaemia and 
hypertension, and leads to high risk for the develop-
ment of cardiovascular disease (CVD). However, these 
abnormalities are not uniform within the various body-
weight categories.1,2 Investigations in body-size pheno-
types have revealed two distinct groups: the first exhib-
its high body mass index (BMI) and body fat (BF) but 
no cardiometabolic abnormalities; this is often termed 
“uncomplicated obesity or metabolically healthy obe-
sity”.3 The second consists of normal-weight individ-
uals who exhibit cardiometabolic abnormalities, and is 
known as “metabolically obese normal-weight”.4,5
Rheumatoid Arthritis (RA), the most common inflamma-
tory arthritis, associates with increased cardiovascular 
morbidity and mortality6 and a high prevalence of obesi-
ty (>50% of RA patients).7 In these patients, obesity has 
been shown to protect against joint damage8, 9 and CVD 
death10 while at the same time associates with increased 
disease activity,11 presence of CVD risk factors12 and re-
duced quality of life.13 The reasons for such seemingly 
conflicting findings in the existing literature is not clear.14 
The different body-size phenotypes might partly explain 
this discrepancy. The aims of the present study were: 
1) to estimate the prevalence of body-size phenotypes 
among patients with RA; 2) to investigate the associations 
of phenotypes with disease characteristics, inflammation, 
and body composition; and 3) to identify predictors of 
metabolic abnormalities within the various phenotypes.
MateRIals and MethOds
Participants
Patients from the Dudley Rheumatoid Arthritis Co-mor-
bidity Cohort (DRACCO) were included in this study. 
The project had Research Ethics Committee approval 
from the Black Country Ethics Committee and patients 
provided informed consent prior to participation. Pa-
tient characteristics have been previously described in 
detail.15 Out of the 400 patients in the cohort, 363 (262 
female) had complete assessments for BMI, glucose, 
insulin sensitivity, hypertension, and blood lipids; these 
patients were included in the analyses. 
Definition of body-size phenotypes
For this study, we have adopted the definition of Wild-
man et al.1 for the classification of body size phenotypes, 
which is currently considered as the optimum set of cri-
teria for this. It classifies body size phenotypes based 
on BMI (normal-weight: BMI<25kg/m2, over-weight: 
BMI<25-29.9kg/m2, obese: BMI>30kg/m2) and the 
presence of cardiometabolic abnormalities (high blood 
pressure, high triglycerides, low levels of high density 
lipoprotein-HDL, high fasting glucose, and insulin resis-
tance). Patients with 0 or 1 cardiometabolic abnormali-
ties were considered metabolically healthy, while patients 
with 2 or more were considered metabolically abnormal 
(table 1). The use of 2 rather than 3 cardiometabolic 
abnormalities (as in the definition of the metabolic syn-
drome) allows for earlier identification of patients poten-
tially at risk for developing CVD.1 Due to the systemic 
inflammation associated with RA, we decided not to in-
clude C-reactive protein (CRP) as a cardiometabolic ab-
normality, since almost 100% of our participants would 
be positive for this. All patient characteristics according 
to phenotype allocation are presented in table 2.
assessments
All assessments have been previously described in 
detail.15 Briefly, standing height and weight were as-
sessed and BMI was calculated (kg/m2); waist cir-
cumference was also assessed. Cut-offs for increased 
waist circumference were >102cm for males or >88cm 
for females.16 Body composition (body fat and fat free 
mass) was assessed by Bioelectrical Impedance (Tani-
ta BC-418 MA Segmental Body Composition Analyzer, 
Tanita Corporation, Tokyo, Japan).
Inflammation was assessed by the erythrocyte sed-
imentation rate (ESR) and CRP. The Disease Activity 
Score-28 (DAS28) was used to assess clinical dis-
ease activity.17 The anglicised version of the Stanford 
Health Assessment Questionnaire (HAQ)18 was used 
to measure functional disability. Disease duration and 
RA medication were assessed by review of patients’ 
clinical notes.
Blood pressure (BP) was assessed as previously de-
scribed.15 Briefly, BP was assessed, after at least 5min 
rest, on the right arm with the patient in a seated po-
sition. Reported value is the mean of three measure-
ments taken at 5min intervals. Blood lipids, glucose 
and insulin were assessed in venous blood collected 
in the fasting state. Insulin sensitivity was evaluated 
with the Homeostasis Model Assessment of insulin 
resistance (HOMA =[Glucose x Insulin]/22.5)19 and the 
Quantitative Insulin sensitivity Check Index (QUICKI =1/
[logInsulin+logGlucose]).20 Smoking status was record-
ed by patient self-report.
Data Management and Analyses
The Kolmogorov-Smirnov test of normality was used 
to assess dispersion of the data. Dispersion is reported 
as mean (standard deviation) or median (interquartile 
range). Results of the logistic models are reported as 
odds ratio with 95% confidence intervals (OR, 95% CI). 
Statistical significance was set at p<0.05.
The frequency of occurrence of each phenotype was 
examined in the descriptive statistics of the sample. 
Cross-tabulations with χ2 analyses were performed 
to identify differences in the prevalence of cardiomet-
abolic abnormalities between body sizes. Analysis of 
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Variance (ANOVA) was used to test for differences 
between the various phenotypes in disease charac-
teristics and inflammation. Finally, regression analyses 
were used to identify predictors of dysmetabolism (i.e., 
presence of 2 or more out of 5 metabolic abnormalities 
as defined above) among the various phenotypes. The 
initial models included the following as covariates: age, 
gender, smoking, BMI, body fat (BF), waist circum-
ference, ESR, RA duration, RA medication (NSAIDs, 
methotrexate, steroids, and biologics). Variables with 
the least contribution to the model were eliminated until 
only significant variables remained.
Results
Prevalence of body-size phenotypes in RA
In the total sample, 44% of the patients were meta-
bolically unhealthy (i.e., had ≥2 cardiometabolic abnor-
malities). The prevalence of metabolic abnormality was 
54.5% for males and 40.5% for females (p=0.011). 
Among normal-weight, 25% were metabolically un-
healthy. Gender specific prevalence was 36.8% for 
males and 22.2% for females. In overweight patients, 
45.8% had metabolic complications, 56% of males and 
40.8% of females. Finally, 57.1% of obese individuals 
were metabolically unhealthy. Again, male participants 
had a higher prevalence of metabolic abnormalities 
(62.5%) compared to females (55.2%).
Association of phenotypes with disease 
characteristics, inflammation, and body 
composition
Patients with metabolic abnormalities were compared 
to metabolically healthy patients within the same BMI 
categories. No statistically significant differences be-
tween groups were detected by ANOVA for any of the 
disease characteristics or markers of inflammation as-
sessed (table 2). However, patients with metabolic ab-
normalities tended to score slightly higher in all of these 
assessments. 
Similarly, no statistically significant differences for mea-
sures of body composition were found between groups, 
apart from normal-weight patients, where metabolically 
healthy patients had significantly smaller waist circum-
ference compared to metabolically unhealthy patients 
(84cm±7.5 vs. 90.5cm±8.5 respectively; p=0.007). 
Moreover, there was a tendency for higher waist cir-
cumference in all metabolically abnormal patients com-
pared to their metabolically healthy counterparts.
Predictors of metabolic abnormalities
Among the various different models used, regression 
analyses identified 3 significant predictors for metabol-
ically unhealthy patients among all body sizes: older 
age (B= 1.032, err=0.011; p= 0.005), ex-smoker (B= 
1.425, err= 0.169; p=0.036), and larger waist circum-
ference (B= 1.057, err= 0.011; p= 0.000).
table 1. Body-size phenotype grouping criteria
Groups criteria
Normal weight, metabolically healthy BMI<25.0 
<2 cardiometabolic abnormalities
Normal weight, metabolically unhealthy BMI<25.0 
≥2 cardiometabolic abnormalities
Overweight, metabolically healthy BMI 25.0-29.9 
<2 cardiometabolic abnormalities
Overweight, metabolically unhealthy BMI 25.0-29.9 
≥2 cardiometabolic abnormalities
Obese, metabolically healthy BMI≥30.0
<2 cardiometabolic abnormalities
Obese, metabolically unhealthy BMI≥30.0 
≥2 cardiometabolic abnormalities
Cardiometabolic abnormalities
1) High blood pressure: ≥140mmHg systolic, or ≥90mmHg, or on anti-hypertensive medication 
2) High triglycerides: >1.7mmol/L
3) Low HDL (high density lipoprotein): <1.03mmol/L
4) High glucose: >5.5mmol/L
5) Insulin Resistance: HOMA≥2.5, or QUICKI≤0.333, or diagnosis for diabetes, or anti-diabetic medication 
37
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table 2. Participants’ characteristics by body-size phenotype
Metabolically Healthy Metabolically Abnormal
Total Normal Weight Over-weight Obese Normal Weight Over-weight Obese
Prevalence  (%, N) 100 (362) 18.7 (68) 22.9 (83) 14 (51) 6.3 (23) 19.3 (70) 18.7 (68)
demographics
Female (%) 72.2 80.4 73.5 76.5 71.6 65 70.6
Age, years 61 (12.1) 59.5 (13.5) 60.1 (12.4) 55.8 (11.3) 65.4 (12.7) 62.2 (10.5) 63.6 (10.7) †
Smoking (%)
current 16.9 25.4 18.3 4 17.4 20.9 11.9
Former 37.9 22.4 34.1 34 43.5 41.8 55.2
Adiposity
BMI (kg/m2) 28.2 (4.7) 22.6 (1.4) 27.1 (1.4) 33.2 (3.1) 23.1 (1.1) 27.1 (1.4) 34 (3.1)
Body Fat (%) 35.7 (8) 29.5 (7.1) 35.2 (6.8) 41.9 (6) 33.7 (5.6) 33.6 (7) 40.6 (7.2)
FFM (kg) 48.4 (10.3) 42.3 (8.6) 47.5 (9.7) 51.6 (9.1) 41.8 (6.9) 49.4 (10.1) 54.2 (10.5)
Waist (cm) 98.5 (12.5) 84 (7.5) 96.4 (6.3) 106.8 (10) 90.5 (8.5)* 99.3 (8.2) 111 (10.6)
Cardiometabolic Factors
Systolic BP (mmHg) 141.7 (20.2) 131.1 (18.4) 139.2 (18.4) 138.6 (21.8) 143.1 (16.2) 145.1 (19.2) 152.3 (19.8)†
Diastolic BP (mmHg) 79 (11.3) 75.1 (11.1) 79.7 (9.9) 79.3 (10.9) 77.2 (13.7) 80.5 (11.4) 81 (11.6)
Hypertension (%) 69.7 32.4 63.9 52.9 95.7* 92.9# 94.1†
Triglycerides (mmol/L) 1.4 (0.7) 1.2 (0.4) 1.2 (0.4) 1.1 (0.3) 1.6 (0.6) 1.8 (0.9) # 1.8 (0.8)†
High Triglycerides (%) 30 7.4 6 5.9 52.2* 50# 60.3†
HDL (mmol/L) 1.6 (0.4) 1.7 (0.5) 1.7 (0.4) 1.6 (0.4) 1.7 (0.4) 1.4 (0.5)# 1.4 (0.4) †
Low HDL (%) 9.6 2.9 0 3.9 8.7* 24.3# 17.6†
Glucose (mmol/L) 5.2 (1.4) 4.8 (0.1) 4.7 (0.4) 4.9 (0.4) 5.6 (0.3) 5.8 (1.5) 5.7 (1.5)
High Glucose (%) 17.6 1.5 1.2 5.9* 21.7* 32.9# 45.6†
HOMA 1.9 [2] 1.2 [1] 1.5 [1.1] 1.6 [1] 2.5 [2.7]* 3.3 [3.8]# 3.5 [3.6] †
QUICKI 0.35 (0.05)
0.38 
(0.04)
0.37 
(0.03)
0.37 
(0.03) 0.33 (0.04)* 0.32 (0.04)
# 0.31 
(0.03) †
Insulin resistance (%) 38 8.8 6 7.8 69.6* 71.4# 83.8†
Ra characteristics
Disease Duration (years) 12.5 (10.5) 13.3 (10.1) 13.2 (10.7) 10.1 (7.3) 13.4 (10.9) 13.3 (10.6) 11.7 (10)
ESR (mm/H) 20 [28] 16 [30] 18 [25] 22 [22] 19 [22] 22.5 [22] 24.5 [30]
CRP (mg/L) 8 [15] 7 [13] 8 [10] 11 [15] 8.5 [20] 9 [17] 10.5 [19]
HAQ 1.4 (0.9) 1.3 (0.9) 1.3 (0.9) 1.4 (0.9) 1.4 (0.9) 1.5 (0.95) 1.6 (0.87)
DAS 4.2 (1.4) 3.9 (1.4) 4.1 (1.3) 4.2 (1.4) 4.4 (1.6) 4.3 (1.3) 4.4 (1.5)
* Significantly different to metabolically healthy normal weight (p<0.05)
# Significantly different to metabolically healthy overweight (p<0.05)
† Significantly different to metabolically healthy obese (p<0.05)
BMI: body mass index; BP: blood pressure; CRP: C-reactive protein; DAS: disease activity score 28; ESR: erythrocyte sedimentation rate; FFM: fat free mass; HAQ: health as-
sessment questionnaire; HDL: high density lipoprotein; HOMA: homeostasis model assessment of insulin resistance; LDL: low density lipoprotein; N: number; QUICKI: quantitative 
insulin sensitivity check index.
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dIsCussIOn
The aim of this study was to investigate the prevalence 
of metabolic complications in different body-size phe-
notypes in RA patients, to test their associations with 
disease activity, and to identify potential predictors of 
such metabolic complications in these phenotypes. To 
our knowledge, this is the first study to investigate this 
in RA. 
We were able to identify 6 different body-size pheno-
types among patients with RA. Most importantly, we 
identified several normal-weight patients with meta-
bolic abnormalities as well as overweight and obese 
patients without any such abnormalities.  In the general 
population,1 the prevalence of normal-weight individu-
als with metabolic abnormalities is very similar to that 
reported here for RA (23.5% vs 25%, respectively). 
This is also the case for overweight patients (51.3% 
vs 45.8%), However, there seems to be a large differ-
ence in the percentage of obese patients with RA that 
exhibit cardiometabolic complications compared to the 
general population: in our RA population, 57.1% of the 
obese participants had such complications, compared 
to almost 70% reported in the general population. We 
need to note that a large percentage of our population 
is female (>60%) and, as we have shown in our results, 
females tend to have less metabolic complications 
compared to males (55.2% vs 62.5% respectively in 
our sample). In a sample with more male participants, 
prevalence of metabolic complications could be higher 
but still, based on our findings, lower than that of the 
general population. 
In the present study, we used the general BMI cate-
gorisation instead of our previously published RA spe-
cific BMI cut-off points (i.e., 23kg/m2 and 28kg/m2 
for overweight and obesity respectively),7 so that our 
findings can be directly comparable to that of the ex-
isting literature in other populations. However, the use 
of RA-specific BMI cut-off points yields similar results 
for the subgroups (i.e., 22.4%, 48.9%, 60.1% among 
normal-weight, overweight and obese exhibit metabol-
ic complications). Thus, the use of these cut-off points 
does not change the essence of our findings.
In the existing literature, a protective effect of obesity 
in RA, both in terms of disease activity8,9 and cardio-
vascular risk10 has been reported. Our data, similarly to 
observations in the general population,21 does not sup-
port this: metabolic complications are more prevalent 
in obese than in overweight or normal-weight patients. 
However, they do support the notion that obesity may 
have a lesser impact - at least in terms of metabolic 
complications - in RA, compared to the general pop-
ulation.22 In general, obese individuals exhibit, in ab-
solute terms, larger fat-free mass compared to leaner 
individuals. In RA, loss of fat-free mass, and especially 
muscle mass, is very common23 and is mostly observed 
in normal-weight patients, while excessive body weight 
seems to be accompanied by a relative preservation 
of fat-free mass.24 Since the muscle is where most of 
the metabolic activity occurs, increased muscle mass 
may counteract some of the negative effects of obesity 
and help some obese RA patients maintain a healthier 
metabolism than their counterparts in the general pop-
ulation. 
In the present study, we were unable to find any signif-
icant differences in disease characteristics and inflam-
mation between body-size phenotypes. However, met-
abolically healthy patients tended to have smaller waist 
circumference compared to metabolically unhealthy. 
Central adiposity is a well-established risk factor for 
CVD and its assessment is included in several of the 
definitions for the metabolic syndrome.25 Excess ab-
dominal adiposity is considered to be one of the main 
causes of metabolic complications; enlarged adipose 
tissue secretes a number of bioactive molecules called 
adipokines.26 These participate in a number of met-
abolic processes which can inhibit the expression of 
several genes (such as GLUT4 and PPARγ) associated 
with transportation of glucose or production and sensi-
tisation of insulin; they also promote lipolysis and thus 
increase the levels of circulating free fatty acids, while 
they may also act directly on insulin signalling.27 These 
mechanisms may reduce insulin action in the muscle, 
and cause endothelial dysfunction,28,29 hypertension,30 
and eventually CVD.31 The significance of central ad-
iposity is further supported by the fact that body fat 
percentages were very similar between body-weight 
phenotypes; indicating that overall fat may be a lesser 
factor for the development of metabolic complications 
than body fat distribution. Moreover, the gender dif-
ferences initially observed became insignificant when 
waist circumference was introduced in the models, as 
is indeed the case in the general population.1 These 
observations highlight the importance for the assess-
ment of central adiposity.
In addition to waist circumference, smoking cessation 
was identified as a significant predictor for metabolic 
complications. We have shown previously32 that within 
RA, ex-smokers exhibit high body fat content and in-
creased waist-circumference; both of which may con-
tribute to metabolic complications. However, the fact 
that ex-smoking was an independent predictor of met-
abolic complication may indicate the existence of other 
mechanisms. Finally, old age was also an independent 
predictor of metabolic complications. Aging associates 
with a number of significant changes, including an-
thropometric and lifestyle alterations, neuro-hormonal 
variations, and increases in oxidative stress; resulting 
in reduced insulin sensitivity33,34 which is implicated in a 
number of mechanisms leading to CVD.35 This is also 
evident among our patients: metabolically healthy pa-
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tients were significantly younger than their metabolical-
ly unhealthy counterparts.   
This study proves that the assessment of obesity, in 
terms of BMI alone, is not a sufficient indicator of met-
abolic state.36 This might partly explain the conflicting 
evidence for the impact of obesity on the health of RA 
patients. Studies investigating obesity in RA should try 
to stratify patients according to body-size phenotypes 
and analyse their data accordingly. Furthermore, the 
identified predictors of subtype allocation (i.e., older 
age, higher waist circumference, and smoking status) 
should be systematically included as potential con-
founders in analyses of such studies. Essentially, our 
findings point towards a combination of assessments 
for obesity. However, further studies are needed before 
we can propose specific methods for that purpose.
The results of this study should be interpreted with 
caution. This is a cross-sectional study and results do 
not provide definitive evidence for causality or direc-
tionality. Furthermore, comparisons with the general 
population are based on the existing literature and not 
directly on a local control group. Race, physical activity 
and diet - all significant aspects in the study of obesity 
- were not assessed. On the other hand, the size of the 
cohort and the prospective collection of data in a stan-
dardised, systematic manner are important strengths, 
as they minimised missing values and selection bias, 
and allowed adjustment for potentially important con-
founders. The method of classification in body size 
phenotypes, despite being widely used, does not al-
low for quantitative evaluation of the cardiometabolic 
abnormalities. In this way, a patient with a value just 
above the cut-off point (e.g., blood pressure of 140/90 
mmHg) will be classified in the same group as a patient 
with a very high value (e.g., blood pressure 180/100 
mmHg). However, this is the case for other classifica-
tion methods, such as the metabolic syndrome, which 
serve primarily for identifying patients at risk for adverse 
effects and do not dictate medical interventions.25
In conclusion, within its limitations, this study identified 
a number of different body-size phenotypes among RA 
patients. One in 4 normal-weight patients has metabol-
ic complications, while >40% of obese RA patients are 
metabolically healthy. Old age, waist circumference and 
smoking cessation are significant predictors for met-
abolic complications among the various body-sizes, 
whereas (current) inflammation or physical dysfunction 
do not appear to be as important. Yet, the underlying 
mechanisms by which these or other factors influence 
metabolism in RA are far from clear and require further 
investigation. Further research focusing on specific ad-
ipose depots and their metabolic properties should be 
conducted.
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